Indiana State
Story Poster
Around CFB: 'Unfit' CFP committee leaves A&M stagnant at No. 3
9 days ago by Olin Buchanan
Whenever the CFP committee tries to explain the reasons No. 3 Texas A&M is ranked behind No. 2 Indiana, it reinforces the fact that the committee is unnecessary and arguably unfit. Even so, the Aggies only need one win out of their three remaining to secure a spot in the 12-team field.
Story Poster
6:22
Liucci offers his thoughts as A&M holds steady in CFP rankings
9 days ago by Billy Liucci
Sitting at 9-0 and 6-0 in SEC play, Texas A&M came in at No. 3 in the second College Football Playoff rankings, released on Tuesday night. TexAgs' co-owner and executive editor Billy Liucci joined TexAgs Live to discuss the committee's selections and more.
Story Poster
Projecting college baseball's top-16 seeds as regular season winds down
1 yr ago by David Sandhop
We are just 26 days away from the 2024 NCAA Tournament Selection Show. As college baseball programs finish out their respective seasons, we took a look at the top 16 teams in RPI ranking, which includes your Fightin' Texas Aggies at the top of the list.
Get access to all Premium content today
Start your subscription for just $1
Try Premium Now
Story Poster
13:40
D1Baseball's Kendall Rogers grades Texas A&M's 2023 campaign
2 yr ago by Nick Savage
Texas A&M's postseason may be done, but there are still 16 teams vying for a spot in Omaha. On Wednesday, D1Baseball's Kendall Rogers joined TexAgs Radio to recap the Ags' showing in Stanford and preview the super regional round this weekend.
Story Poster
11:01
Peterson: A&M will face true old-school, west coast offense vs. CS Fullerton
2 yr ago by David Nuño
Former Stanford All-American and ESPN baseball analyst Kyle Peterson joined TexAgs Radio to preview the field in Palo Alto this coming weekend. Peterson elaborated on what Texas A&M can expect with Cal State Fullerton's style of play as well as his alma maters.
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.